Skip to main content

Table 6 Regression analysis of variables affecting change in CAARS:O-SV score (completer population)

From: Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial

Variable

Point estimate

p-value

Difference in least squares means

p-value

Treatment group

    

 54 mg

–4.6356

0.0039

–3.0139

0.0247

 72 mg

–6.9787

< 0.0001

–4.6818

0.0004

Baseline CAARS:O-SV score

–0.3721

< 0.0001

Prior adherence

–0.1423

< 0.0001

No family history of ADHD

3.9342

0.0003

Time point × Treatment group

    

 Week 1 × 54 mg

4.6305

0.0078

–0.0051

0.9975

 Week 1 × 72 mg

6.0762

0.0004

–0.9025

0.5672

 Week 3 × 54 mg

2.3155

0.1476

–2.3201

0.1468

 Week 3 × 72 mg

3.2686

0.0390

–3.7101

0.0189

 Week 5 × 54 mg

2.1577

0.1294

–2.4779

0.1213

 Week 5 × 72 mg

2.2344

0.1121

–4.7443

0.0027

 Week 7 × 54 mg

0.6507

0.6197

–3.9849

0.0128

 Week 7 × 72 mg

1.9795

0.1268

–4.9992

0.0016

 Week 9 × 54 mg

–0.0242

0.9829

–4.6598

0.0036

 Week 9 × 72 mg

0.2229

0.8419

–6.7558

< 0.0001

DUSI: family system

–0.0551

0.0583